Edmond DE Rothschild Holding S.A. Takes $62.03 Million Position in Bruker Corporation $BRKR

Edmond DE Rothschild Holding S.A. acquired a new stake in Bruker Corporation (NASDAQ:BRKR) in the second quarter, Holdings Channel.com reports. The fund acquired 1,505,639 shares of the medical research company’s stock, valued at approximately $62,032,000. Bruker accounts for 1.0% of Edmond DE Rothschild Holding S.A.’s holdings, making the stock its 20th largest holding.

Other institutional investors also recently bought and sold shares of the company. Allianz Asset Management GmbH purchased a new stake in shares of Bruker in the 1st quarter valued at approximately $363,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Bruker by 1.2% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 50,106 shares of the medical research company’s stock valued at $2,091,000 after acquiring an additional 572 shares during the last quarter. Fiera Capital Corp grew its position in Bruker by 3.6% in the first quarter. Fiera Capital Corp now owns 47,211 shares of the medical research company’s stock worth $1,971,000 after acquiring an additional 1,643 shares during the period. GSA Capital Partners LLP purchased a new position in Bruker in the first quarter worth approximately $941,000. Finally, XTX Topco Ltd acquired a new stake in Bruker during the first quarter worth $627,000. 79.52% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Bruker

In other Bruker news, Director John A. Ornell sold 6,233 shares of the stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $39.00, for a total value of $243,087.00. Following the sale, the director owned 35,212 shares of the company’s stock, valued at $1,373,268. This trade represents a 15.04% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Cynthia M. Friend sold 3,535 shares of the business’s stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $32.25, for a total value of $114,003.75. Following the transaction, the director directly owned 18,016 shares of the company’s stock, valued at approximately $581,016. This represents a 16.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 27.30% of the stock is currently owned by company insiders.

Bruker Stock Up 0.6%

Shares of BRKR opened at $47.56 on Tuesday. The company’s 50-day simple moving average is $37.62 and its 200-day simple moving average is $37.33. The company has a debt-to-equity ratio of 1.31, a quick ratio of 0.70 and a current ratio of 1.61. Bruker Corporation has a 1 year low of $28.53 and a 1 year high of $64.64. The stock has a market capitalization of $7.23 billion, a PE ratio of 91.46, a P/E/G ratio of 5.31 and a beta of 1.26.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings data on Monday, November 3rd. The medical research company reported $0.45 earnings per share for the quarter, beating analysts’ consensus estimates of $0.33 by $0.12. The firm had revenue of $860.50 million during the quarter, compared to analysts’ expectations of $847.40 million. Bruker had a net margin of 2.31% and a return on equity of 17.89%. The business’s quarterly revenue was down .5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.60 earnings per share. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. Analysts forecast that Bruker Corporation will post 2.69 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 2nd. Stockholders of record on Monday, December 8th will be given a dividend of $0.05 per share. The ex-dividend date of this dividend is Monday, December 8th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.4%. Bruker’s dividend payout ratio is currently -125.00%.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. Citigroup lowered their price target on Bruker from $40.00 to $38.00 and set a “neutral” rating for the company in a report on Monday, August 4th. Barclays upped their target price on shares of Bruker from $40.00 to $45.00 and gave the company an “overweight” rating in a research report on Tuesday, November 4th. Rothschild Redb upgraded shares of Bruker to a “strong-buy” rating in a research report on Thursday, November 20th. Stifel Nicolaus set a $40.00 price objective on shares of Bruker and gave the stock a “hold” rating in a report on Tuesday, August 5th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Bruker in a research report on Wednesday, November 19th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $50.25.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.